Crinetics Pharmaceuticals Inc (CRNX)
$60.15 $1.84 (3.22%) 4:38 PM 12/11/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$5.46B -
Day's Range
$57.02 - $59.63 -
Volume
573,248 -
52 Week Low / High
$32.56 - $62.53 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 8
- Strong Buy
- 5
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong Sell
- $46.89
- Target Price
Company News
-
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 — Oct 16th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024 after the market closes. Company management will host a confer...
-
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — Oct 10th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggr...
-
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock — Oct 8th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relat...
-
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 — Oct 16th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024 after the market closes. Company management will host a confer...
-
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock — Oct 9th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relat...
-
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock — Oct 9th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relat...
-
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock — Oct 8th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relat...
-
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — Oct 10th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggr...
-
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly — Sep 26th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral, selective...
-
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — Oct 10th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggr...
-
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock — Oct 8th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relat...
-
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock — Oct 8th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relat...
-
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock — Oct 9th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relat...
-
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock — Oct 9th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relat...
-
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly — Sep 26th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral, selective...
-
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock — Oct 9th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relat...
-
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock — Oct 9th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relat...
-
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock — Oct 9th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relat...
-
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — Oct 10th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggr...
-
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — Oct 10th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggr...
-
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock — Oct 8th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relat...
-
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 — Oct 16th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024 after the market closes. Company management will host a confer...
-
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 — Oct 16th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024 after the market closes. Company management will host a confer...
-
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 — Oct 16th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024 after the market closes. Company management will host a confer...
-
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly — Sep 26th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral, selective...
-
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock — Oct 9th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relat...
-
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — Oct 10th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggr...
-
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 — Oct 16th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024 after the market closes. Company management will host a confer...
-
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — Oct 10th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggr...
-
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock — Oct 8th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relat...
-
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock — Oct 8th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relat...
-
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 — Oct 16th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024 after the market closes. Company management will host a confer...
-
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 — Oct 16th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024 after the market closes. Company management will host a confer...
-
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock — Oct 9th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relat...
-
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — Oct 10th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggr...
-
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock — Oct 8th, 2024
Crinetics Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relat...
Similar Stocks
Portfolio
Comprised of 1 portfolios